Evidence map›Paper›PMID 36261002›Full record

ArticleCell reports2022

Oligodendroglial macroautophagy is essential for myelin sheath turnover to prevent neurodegeneration and death.

Etan R Aber, Christopher J Griffey, Tim Davies, Alice M Li, Young Joo Yang, Katherine R Croce, James E Goldman, Jaime Grutzendler, Julie C Canman, Ai Yamamoto

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Disruption to TFEB signaling and autophagy in newly formed oligodendrocytes leads to aberrant generation of CNS myelin.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Etan R AberDoctoral Program in Neurobiology and Behavior, Medical Scientist Training Program, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA.
Christopher J GriffeyDoctoral Program in Neurobiology and Behavior, Medical Scientist Training Program, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA.
Tim DaviesDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Biosciences, Durham University, Durham DH1 3LE, UK.
Alice M LiDepartment of Neurology and Neuroscience, Yale University, New Haven, CT 06515, USA; Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, CT 06510, USA.
Young Joo YangGraduate Program in Pathobiology and Molecular Medicine, Columbia University, New York, NY 10032, USA.
Katherine R CroceDepartment of Neurology, Columbia University, New York, NY 10032, USA; Graduate Program in Pathobiology and Molecular Medicine, Columbia University, New York, NY 10032, USA.
James E GoldmanDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Jaime GrutzendlerDepartment of Neurology and Neuroscience, Yale University, New Haven, CT 06515, USA.
Julie C CanmanDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Ai YamamotoDepartment of Neurology, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. Electronic address: ai.yamamoto@columbia.edu.
Columbia University · USYale University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1M
The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal DementiaR01NS127186 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOLT, LIAM J, PHATNANI, HEMALI · 2021 to 2025
$8.2M
NEUROBIOLOGY OF CORTICAL SYSTEMST32NS007224 · NINDS · YALE UNIVERSITY · PI CARDIN, JESSICA A · 1985 to 2025
$4.6M
Modulating selective autophagy to modify Huntington's diseaseR01NS077111 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ai Yamamoto · 2012 to 2026
$4.3M
Autophagy and NeurodegenerationR01NS063973 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MELIA, THOMAS JAMES, YAMAMOTO, AI · 2008 to 2019
$3.8M
Molecular probes to image and target the neurovascular unit in health and diseaseR01NS115544 · NINDS · YALE UNIVERSITY · PI GRUTZENDLER, JAIME · 2020 to 2024
$3.1M
Selective autophagy in Parkinson'sdiseaseR01NS101663 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ai Yamamoto · 2018 to 2026
$3.1M
Cell type-variation of cytokinesisR01GM117407 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CANMAN, JULIE C · 2016 to 2023
$2.9M
Therapeutic targeting of angiophagy to achieve microvascular recanalizationR01NS111961 · NINDS · YALE UNIVERSITY · PI GRUTZENDLER, JAIME · 2019 to 2023
$2.3M
Probing the spatiotemporal regulation of cell divisionR01GM130764 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CANMAN, JULIE C · 2019 to 2022
$1.3M
Identification of the initial cellular site of action of a-synuclein in the pathogenesis of Parkinson's disease in vivo.R01NS102172 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YAMAMOTO, AI · 2017 to 2018
$630k
NIGMS NIH HHS R01 GM117407NIGMS NIH HHS R01 GM130764NIGMS NIH HHS T32 GM007205NIGMS NIH HHS T32 GM007367NINDS NIH HHS F31 NS118897NINDS NIH HHS R01 NS063973NINDS NIH HHS R01 NS077111NINDS NIH HHS R01 NS101663NINDS NIH HHS R01 NS102172NINDS NIH HHS R01 NS111961NINDS NIH HHS R01 NS115544NINDS NIH HHS R01 NS127186NINDS NIH HHS R21 NS118891NINDS NIH HHS T32 NS007224
6 · The paper itself

Abstract

Although macroautophagy deficits are implicated across adult-onset neurodegenerative diseases, we understand little about how the discrete, highly evolved cell types of the central nervous system use macroautophagy to maintain homeostasis. One such cell type is the oligodendrocyte, whose myelin sheaths are central for the reliable conduction of action potentials. Using an integrated approach of mouse genetics, live cell imaging, electron microscopy, and biochemistry, we show that mature oligodendrocytes require macroautophagy to degrade cell autonomously their myelin by consolidating cytosolic and transmembrane myelin proteins into an amphisome intermediate prior to degradation. We find that disruption of autophagic myelin turnover leads to changes in myelin sheath structure, ultimately impairing neural function and culminating in an adult-onset progressive motor decline, neurodegeneration, and death. Our model indicates that the continuous and cell-autonomous maintenance of the myelin sheath through macroautophagy is essential, shedding insight into how macroautophagy dysregulation might contribute to neurodegenerative disease pathophysiology.

Indexed as

Myelin SheathNeurodegenerative DiseasesAnimalsCentral Nervous SystemMacroautophagyMiceOligodendrogliaAlfy/Wdfy3amphisomeautophagosomeCP: Neurosciencemyelinneurodegenerationoligodendrocyteselective autophagy

Identifiers

PMID36261002
PMCPMC9639605
OpenAlexW4306746351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.